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ABSTRACT 
Nonalcoholic fatty liver disease (NAFLD) is currently a worldwide problem 
associated with diabetes, obesity, heart diseases, and insulin resistance. The pathogenesis 
of NAFLD is divided into simple steatosis, through nonalcoholic steatohepatitis (NASH) 
to fibrosis and cirrhosis finally, lipid deposition and chronic inflammation are the main 
markers. There is still no effective medicine for the therapy of NAFLD, specifically in 
the NASH stage. 
Berberine (BBR) is a natural product isolated from plants such as Coptis 
chinensis Franch, and it has been reported it had beneficial pharmacological activities in 
a series of metabolic diseases, focusing on adenosine monophosphate-activated protein 
kinase (AMPK) pathway. BBR showed anti-hyperglycemic and anti-hyperlipidemic 
effects in diabetes and obesity patients and animal models. It improved insulin 
sensitivity in these reports and our experiment. We found BBR improved insulin 
resistance and glucose intolerance in HFD mice, without body weight or food intake 
difference. BBR ameliorates fat deposition in liver, through reducing lipogenesis related 
genes expression. Meanwhile, BBR decreased inflammation in liver and adipose tissue. 
BBR inhibited JNK pathway and activated AMPK phosphorylation in hepatocytes, but 
not in the macrophages. Thus, the function cells may be the main cell type that responds 
to BBR in liver, and maybe BBR down-regulates lipogenesis through inhibiting Akt. 
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Abbreviations Full Name 
ACC Acetyl-CoA carboxylase 
AMPK AMP-activated protein kinase 
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BMDM Bone marrow-derived macrophages 
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JNK1 c-jun N-terminal protein kinase 1 
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LDLR Low-density-lipoprotein receptor 
LFD Low-fat diet 
MDA Malondialdehyde 
NAFLD Nonalcoholic fatty liver disease 
NASH Nonalcoholic steatohepatitis 
NF-κB Nuclear factor-κB 
PUFAs Polyunsaturated fatty acids 
PVDF Polyvinylidene difluoride 
L-PK Pyruvate kinase 
RT-PCR Quantitative real-time polymerase chain reaction 
ROS Reactive oxygen species 
SAA3 Serumamyloid A3 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gels 
SCD Stearoyl-CoA desaturase 
SREBP-1c Sterol regulatory element–binding protein-1c 
SOD Superoxide dismutase 
TZD Thiazolidinediones 
TLR4 Toll-like receptor 4 
TNFa Tumor necrosis factor alpha 
T2DM Type 2 diabetesmellitus 
VLDL Very low-density lipoprotein 
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1. INTRODUCTION
It was reported more than 30 million Americans were affected by Nonalcoholic 
fatty liver disease (NAFLD), which starts from lipid accumulation in hepatocytes, 
without consuming excessive alcohol. NAFLD is commonly linked with dyslipidemia, 
insulin resistance, and accompanied chronic inflammation, and it always represents a 
bystander and risk (steatosis) for the metabolic syndrome, including hypertension, type 2 
diabetes, and cardio-vascular disease(1,2). 
By now, there is no specific medicine in the treatment of NAFLD. In clinic guild 
line books, lifestyle modification such as more physical activity and less caloric intake is 
still considered as best therapy method, insulin-sensitizing agents including 
thiazolidinediones (TZD) and metformin will be used as adjuvant drugs. In Asia, 
because of long history development and utilization of herbs, many research focused on 
the drugs isolated from natural products. 
Berberine is a kind of isoquinoline alkaloid presents in many plants. In the past 10 
years, in many clinic trials, it has been proven to be an effective agent in controlling 
dyslipidemia and dysglycemia of type 2 diabetes and CVD(3). In some research, BBR is 
reported to up-regulate hepatic LDLR expression in HepG2 cells(4), and reduce fatty 
liver development in high-fat diet fed mice or obese db/db and ob/ob mice(5). The 
precise mechanisms of benefits of BBR for NAFLD are unclear. Multiple mechanisms 
involved in inflammation, lipid metabolism, and insulin resistance pathways, were 
considered playing important roles. 
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1.1 Nonalcoholic Fatty Liver Disease 
Presently, Nonalcoholic fatty liver disease (NAFLD) is a widely common liver 
disorder in worldwide. NAFLD may affect persons of all ages and most racial groups. 
Nonalcoholic fatty liver disease is associated with insulin resistance and 
hyperinsulinemia even in lean individuals with normal glucose tolerance. 
1.1.1 Prevalence 
 “Nonalcoholic steatohepatitis” has been recognized as a clinical syndrome since 
1962. These patients were diagnosed with increased serum alanine aminotransferase 
levels but not as high as the alcoholic hepatitis patients, and some of them would may 
incur further liver injury(6). It was reported almost half of them progressed to liver 
fibrosis, 15% developed cirrhosis, and finally 3% have hepatocellular failure (7). 
NAFLD is frequently associated with type 2 diabetes mellitus, obesity, and dyslipidemia. 
It was reported the prevalence of obesity varied 30% - 100%, among type 2 diabetes the 
prevalence is 10% - 75%, and hyperlipidemia is 20% - 92%(8). 
1.1.2 Diagnosis 
Most NAFLD patients had central fat accumulation, increased triglycerides and uric 
acid, and low HDL cholesterol, irrespective of BMI(8). In the USA, most of the 
abnormal liver function tests (LFTs) results mean a diagnosis of NAFLD. Around 80% 
of the fatty liver could be determined by the ultrasound examination, and serum alanine 
aminotransferase always increased. Serum alkaline phosphatase or γ-glutamyltransferase 
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will increase, and hyperbilirubinemia, a prolonged prothrombin time, and 
hypoalbuminemia may also be found in the NAFLD patients. Sometimes the serum 
ferritin levels and transferrin saturation will elevate, however, the hepatic iron level is 
normal. The relationship of iron metabolism and fatty liver cannot be confirmed. 
 
1.1.3 Pathogenesis 
The mechanism of nonalcoholic fatty liver disease is still not clear and the 
pathogenesis is still being worked out. Generally, the pathogenesis starts from simple 
steatosis (fatty liver), through nonalcoholic steatohepatitis (NASH) to fibrosis, and 
ultimately liver cirrhosis. Day et al.(9) gave a statement of "two-hit" model to describe 
the NAFLD progression. The first hit is insulin resistance causes lipid accumulation in 
hepatocytes. This symptom could be alleviated by modifying lifestyle; in the second hit, 
it was proposed that lipid oxidation, inflammation, and oxidative stress will lead to 
hepatocyte damage, resulting in irreversible NASH. NASH presents liver injury, 
hepatocyte carcinoma, and inflammation, thus it is irreversible. It is poorly understood 
why some of the patients with simple steatosis will develop into steatohepatisis, whereas 
some other will proceed into severe fibrosis and cirrhosis, and some NAFLD patients 
were lean and the fasting serum triglyceride level is normal.  
 
1.1.3.1 Molecular mediators of hepatic steatosis 
NAFLD is always induced by excess dietary fat intake or increased lipolysis in the 
adipose tissues. Abnormal metabolism of lipid and lipoprotein could be considered as a 
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mark of NAFLD, and liver produces excessive cytokines and very low-density 
lipoprotein (VLDL), which result in exacerbated accumulation of triglycerides in the 
liver.  
In the first stage, triglyceride accumulation in the liver is a hallmark of NAFLD. It 
was commonly understood the main reason is insulin resistance. In the insulin resistant 
state, hormone-sensitive lipase (HSL) activity is increased which lead to increased 
release of free fatty acids (FFAs) from adipose tissues. Thus, the plasma FFAs levels 
increase, it also means the amount of FFAs taken up by liver elevates. FFAs taken up by 
the liver are either oxdized to generate ATP in mitochondria or esterification to produce 
triglycerides, which may be stored within the hepatocyte or incorporated into VLDL 
particles. (10)  
In the setting of insulin resistance, insulin will lose its ability to suppress 
gluconeogenesis genes, while hyperinsulinemia induces expression of a membrane-
bound transcription factor, sterol regulatory element–binding protein-1c (SREBP-1c), 
which will lead to the activation of all lipogenisis genes(11). Increased hepatic SREBP-
1c transcription will activate the enzyme Acetyl-CoA carboxylase (ACC), leading to 
increased malonyl-CoA production. Malonyl-CoA is the inhibitor of carnitine palmitoyl 
transferase-1 (CPT-1), the protein transporting fatty acid into the mitochondria. Thus, 
insulin resistance will not only enhance de novo fatty acid synthesis, but also inhibit 
fatty acid β oxidation.  
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Figure 1.1 Processes of glycolysis and lipogenesis in livers of normal individuals. 
When glucose intake is excess, more fatty acids are synthsized. 
The normal process of the lipogenesis and fatty acid β oxidation are shown in 
Figure 1.1. When the intake of glucose is excess, glucose is up-taken by liver and 
converted to pyruvate, which will enter into the TCA cycle in mitochondria, then in the 
cytosol the citrate generated in the TCA cycle will convert into acetyl-CoA. The acetyl-
CoA is the resource of fatty acids synthesis, and it is converted to malonyl-CoA by 
Acetyl-CoA carboxylase 1 (ACC1), and finally palmitic acid. Palmitic acid may be 
desaturated to palmitoleic by acid stearoyl-CoA desaturase (SCD). On the contrast, in 
liver, β oxidation of fatty acids yields acetyl-CoA, NADH and FADH2. NADH and 
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FADH2 will enter into respiratory electron transfer chain and generate ATP. Acetyl-
CoA is used to synthesize ketone bodies, and the ketone bodies travel to non-hepatic 
tissues as energy. The malonyl-CoA generated in the lipogenesis process is the inhibitor 
of Carnitine palmitoyl transferase I (CPT1), which is responsible to exchange carnitine 
for fatty acyl-CoA in cytosol, and this is the first and speed-limited step ofβ oxidation of 
fatty acids. Thus, increased fatty acid synthesis also means inhibit of β oxidation of fatty 
acid. 
Insulin resistance means increased hepatic glucose production and elevated plasma 
glucose concentration. Glucose stimulates ChREBP to bind to an E-box motif of 
pyruvate kinase (L-PK), a glycolysis regulatory enzyme catalyzes phosphoenolpyruvate 
to pyruvate, which is converted to acetyl-CoA in TCA cycle(12). Fatty acid synthesis is 
elevated. 
It seems like there are two directions in the insulin signaling pathway when it 
comes to insulin resistance: the ability of insulin to block glucose production declines, 
and the ability to stimulate fatty acid synthesis is enhanced. Li et al.(13) indicated the 
two different insulin-mediated changes will be blocked by inhibiting PI3K and Akt, and 
a decreased phosphorylation of Akt will lead to decreased mTORC1 activity and, 
therefore, decreased SREBP-1c mRNA, however, there is no effect on insulin 
suppression of PEPCK. 
All the molecular mechanism of hepatic steatosis was summerized in the Figure 1.2. 
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Figure 1.2 A series of molecules participate in the development of hepatic steatosis. 
There was another hypothesis: the excess FFAs in liver would supply more energy 
to promote the excess gluconeogenesis, leading to increased production of hepatic 
glucose. Thus, in the insulin resistant statement, the blocked effect of insulin on 
gluconeogenesis is inhibited but lipogenesis is not in fatty liver.(14) 
AMP-activated protein kinase (AMPK), a sensor of cellular energy storage, is 
considered a key factor in the pathogenesis of hepatic steatosis as well, via 
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phosphorylated regulating ACC, reducing the expression levels of SREBP-1c, and 
inhibiting ChREBP(15). When fasting, cellular AMP levels increase, and AMPK is 
activated, therefore, stimulates ATP production pathway and inhibit ATP utilization 
pathway. AMPK regulate lipid accumulation in liver through phosphorylating enzymes 
involved in lipogenesis and fatty acid β oxidation. 
The insulin-induced lipogenesis may lead to triglyceride accumulation in liver in 
two aspects. One is increased synthesis of triglycerides directly, and another is the 
increased malonyl-CoA production during lipogenesis which will inhibit CPT-1, 
reducing fatty acid β oxidation. 
1.1.3.2 Development of nonalcoholic steatohepatitis (NASH) 
No more than 20% of the NAFLD patients will develop NASH. Most studies of the 
mechanism that hepatic steatosis progresses to NASH are always hypothesis. The simple 
steatosis is a nonprogressive state which could be reversed by modification lifestyle. The 
irreversible stage of NAFLD that the hepatic steatosis develops to NASH could be 
considered as another type of disease because of a different pathogenesis. For example, 
Yamaguchi et al.(16) pointed out that decreased hepatic triglyceride content improves 
liver steatosis but worsens liver damage, through inhibiting triglyceride synthesis via 
Diacylglycerol acyltransferase 2 (DGAT2) antisense oligonucleotides. DGAT2 is the 
enzyme including in the final step of triglyceride synthesis. 
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It was hypothesized that chronic inflammation aggravates the process of NASH, 
and the factors of oxidative stress and pro-inflammatory cytokines are the most 
important factors, shown in Figure 1.3 (17). 
Increased triglycerides and cholesterol accumulation in the hepatocyte 
mitochondria in the early stage of NAFLD can lead to increased oxidative stress. The 
oxidation of free fatty acids through mitochondrial β oxidation pathway actives tumor 
necrosis factor alpha (TNFa) and, therefore, forms reactive oxygen species (ROS)(18), 
which causes liver damage. It was reported metformin and anti-TNF antibody would 
reduce steatosis in ob/ob mice (leptin mutation mice), both of them inhibit TNFa(19,20). 
ROS is the pro-oxidant factor, including superoxide anions, hydroxyl radicals and 
hydrogen peroxide. Increased ROS leads to DNA damage, destruction of cell 
membranes, cellular damage and pro-inflammatory cytokines release(21). An additional 
ROS production is considered to form mitochondrial dysfunction, and mitochondrial 
damage was found in liver biopsy of NASH patients. The mitochondrial impair 
interrupts the electron flow in respiratory chain, then hydrogen peroxide and superoxide 
anions form, and increased cytosolic fatty acids will be oxidized via β oxidation and ω 
oxidation(22,23). On the other hand, polyunsaturated fatty acids (PUFAs) and lipid will 
be the target of ROS for non-enzymatic peroxidation, producing peroxides and their 
degradation products. 
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Figure 1.3 Molecular mechanisms of nonalcoholic steatohepatitis (NASH).  
The inflammatory signalings from other tissues such as adipose tissue and intestine 
would excerbate the process of NASH. 
The oxidation and peroxidation of fatty acids increase secretion of inflammatory 
factors, active immune cells infiltration and the stellate cells in the liver, leading to 
fibrosis and cirrhosis. Park et al.(24) indicated that activation of IL-6 and TNFa will lead 
to liver inflammation. The deletion of one of these two cytokines reduced liver lipid 
content and inflammation in mice. 
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Some researchers suggested inflammatory factors from other tissues such as 
adipose tissue and gut would play a central role in the process of NASH. 
In obesity patients, the infiltration of macrophages (CD11cþ cells) in adipose tissue 
increases, and the macrophages in adipose tissue secret more pro-inflammatory 
cytokines such as TNFα and interleukin-6 (IL-6). The liver is an important target organ 
of the cytokines. In adipose tissue, activation of inflammatory signal transducers c-jun 
N-terminal protein kinase 1 (JNK1) or inhibitor of nuclear factor-κB kinase-β (IKKβ) 
will cause insulin resistance, and insulin resistance will argument inflammation in 
NASH (25), additionally, IL-6 secretion is JNK1 - dependent. Human studies suggested 
liver inflammation is positively related with the amount of fat. Adipocytokines from 
adipose tissue are also considered to affect lipid accumulation and inflammation in 
liver(17). Adiponectin is an anti-inflammatory adipocytokine, and it reduces lipid 
accumulation and improves insulin resistance through activing AMPK in muscle and 
liver. The leptin will promote fatty acid oxidation and improve NAFLD. 
Signals from intestine might induce steatosis and inflammation. Lipopolysaccharide 
(LPS), named endotoxin as well, produced by a lot of bacteria in humans microbiota in 
the gut, was introduced to play a key role in the process of NASH(26). It was invovled in 
the dietary factors activating systemic immune responses, when a high-fat or a high-
carbohydrate diet might stimulate liver steatosis and worsen NASH. Toll-like receptor 4 
(TLR4), expressed on the surface of epithelium and macrophages, may recognize free 
fatty acids and induce secretion of pro-inflammatory factors(27), therefore it play a 
central role in inflammation of obesity and fatty liver. 
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Furthermore, many studies hypothesized inflammation in liver may play a key role 
in the NASH development, companied with increased inflammation markers, such as 
TNF-α, interleukin 6 (IL-6), and serumamyloid A3 (SAA3)(5). 
 
1.1.4 Management 
Lifestyle modification is still suggested as the best therapy method of NAFLD in 
the practice guideline by the American Association for the Study of Liver Diseases(28). 
For example, caloric restriction and increased physical activity, would achieve weight 
loss, and lead to decreased aminotransferases and hepatic steatosis. Heavy amounts of 
alcohol, such as more than 4 drinks/day or 14 drinks/week in men or more than 3 
drinks/day or 7 drinks/week in women, are not recommended in NAFLD patients. 
Insulin sensitizing agents were suggested to assist with life modification in NAFLD 
treatment. The antidiabetic drugs thiazolidinediones and metformin improved hepatic 
steatosis via reducing hepatic fat and decreasing liver size, and it was reported it was 
through activating AMPK, shown in Figure 1.4 (29,30). They are also effective in 
hypoglycemic therapy. 
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Figure 1.4 Metformin and TZD improved hepatic steatosis via AMPK pathway. 
In addition, a daily dose of 800 IU Vitamin E, an anti-oxidant, also improves liver 
histology in biopsy-proven NASH patients without diabetes, and it would improve 
inflammation and ballooning injury. Omega-3 fatty acids are suggested as drugs to treat 
hypertriglyceridemia in NAFLD patients. (28) 
Foregut bariatric surgery could be considered as a potential option for treatment 
NAFLD or NASH without cirrhosis, but the type and safety are still uncertain. 
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From the clinic data, metformin would reduce insulin resistance and 
aminotransferases, but has no significant effect on liver histology in NASH patients. 
Pioglitazone can be used in biopsy-proven NASH patients, but the adverse effect is 
promoting weight gain. Therefore, scientists try to find novel and specific drugs to treat 
NAFLD. In Asian, it is common for the doctors to think about natural compound 
isolated from traditional herb medicines, because of long-termed and widely utilization 
of traditional Chinese medicine. 
1.2 Berberine 
Berberine is the major constituent of a kind of herb named Rhizoma Coptis, which 
has been officially recorded in the ancient traditional Chinese medicine book“Shen 
Nong Elite Physicians” as a powerful drug to treat diarrhea and peptic ulcer for over 
2000 years, characterized its antimicrobial and antiprotozoal properties, it could kill 
most bacteria, viruses, parasites, yeast, fungi, protozoans and Candida albicans. 
However, since from 1988, the first time of discovery of the hypoglycemic effect of 
berberine in China(31), berberine has been utilized in improvement of many metabolic 
diseases. It was reported berberine would decrease energy storage and increase fatty 
acids oxidation, improve insulin sensitivity, protect from CVD, and etc. mostly via 
AMPK pathway (5,32). 
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1.2.1 Chemical structure and pharmacokinetics 
Purified berberine is yellow powder which is difficult to dissolve in water in the 
room temperature, and tastes extremely bitter. It could be isolated from roots, rhizomes, 
stems, and bark of various plants, such as Coptis chinensis (Coptis or goldenthread), 
Berberis vulgaris (barberry), Hydrastis canadensis (goldenseal), and Berberis aristata 
(tree turmeric), and the content is about 5.2% to 7.7%.  
Berberine (BBR, C20H18NO4), an isoquinoline alkaloid, is the protoberberine type, 
there are many derivates, including berberine hydrochloride, berberine sulfate, berberine 
citrate, and berberine phosphate. Generally, berberine sulfate is always used as 
veterinary medicine in form of injection fluid, because of its good solubility in the water, 
while humans can only use berberine hydrochloride p.o. pills because the high 
concentration of NH4
+
 in the blood flux is bad for human.  
It was always thought to be poor oral bioavailability because the blood 
concentration is quite low and hard to be detected in the normal pharmacokinetics 
method. It was found P-glycoprotein located on the surface of epithelial cells prevent the 
absorption of berberine molecular. At least 9 types of derivates have been detected as 
metabolic products after p.o. Ber administration. Zuo et al. (33) studied the metabolites 
of berberine in liver and bile in rats after p.o. administration, via liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) with electrospray ionization. 
Berberrubine (M1), thalifendine (M2), demethyleneberberine (M3), and jatrorrhizine 
(M4), together with original BBR are the major metabolites (Figure 1.5) (33) in liver and 
bile. Previously, it was commonly confused that the plasma BBR concentration was 
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quite below the effective dose in vitro treatment. Zuo et al. detected the BBR and its 
major metabolites in liver tissues only 0.5 h and in bile 1h after p.o. administration. They 
supposed BBR was metabolized in liver fast, thus the clearance of BBR from blood is 
rapid and the concentration is trace, then the metabolites were excreted into the intestine 
by bile. The intestinal flora in humans or rats will promote reabsorption of metabolites 
from jejunum, and the metabolites remained in the rats for a long time to more than 24 
hr. 
Figure 1.5 Chemical structures of berberine and its major metabolites. 
M1 is the most powerful of antitumor activity(34), and BBR and M2 were 
hypothesized the greater active forms of hypolipidemic effect in HepG2 cells(35). In the 
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experiment plan, we chose BBR alone to survey its effect on lipid metabolism in vivo 
and vitro. 
1.2.2 Novel functions in metabolic diseases 
In the recent several decades, BBR was found to decrease blood glucose and lipid 
disorders in humans and animals. It was already found 1500 years ago that the herb 
Rhizoma Coptidis was recorded by Hongjing Tao in the book “Note of Elite Physicians” 
it can be used to treat diabetes. In 1988, it is the first time the hypoglycemic effect of 
berberine was found when doctors use berberine to treat diarrhea in diabetic patients in 
the traditional Chinese Medicine hospital. From then, lots of clinic trials proved the 
safety and effect of BBR in the treatment of type II diabetes mellitus. They used BBR 
alone or combined with oral hypoglycaemics or anti-diabetic agents, BBR has similar 
anti-hyperglycemic and anti-dyslipidemic function as metformin and thiazolidinediones 
(36). From the data analysis of about 700 clinic type 2 diabetesmellitus (T2DM) samples 
collected from published papers between 2007 and 2011, BBR showed a better 
dyslipidemic control than metformin, glipizide, or rosiglitazone, but similar anti-
glycaemic effect. But combination of BBR and those drugs showed a better glycaemic 
control than metformin or TZDs alone(3). 
In Asian, BBR has been used as an anti-hyperglycemic agent in many clinic trials. 
It was reported many time BBR would decrease postprandial blood glucose and lower 
fasting blood glucose in type 2 diabetes patients(3). The insulin resistance index, total 
cholesterol and serum triglyceride were reduced (3,37). It was supposed anti-
 18 
 
hyperglycemic ability of BBR was due to phosphorylating AMPK, leading to inhibit 
gluconeogenesis and increase glucose consumption, and BBR may stimulate glycolysis 
via increase aerobic and anaerobic respiration (38,39). 
Berberine improves insulin sensitivity and reduced fat deposition in obese animals. 
Lee et al. (40) said BBR decreased body weight without altering food intake in db/db 
mice, an animal model of obesity and insulin resistant due to a mutation in the leptin 
receptor gene, maybe through increasing AMPK activity and decreasing phosphorylation 
of ACC in the adipose tissue, as well as increasing GLUT4 translocation in muscle. Cell 
treatment also showed BBR reduced lipid accumulation in 3T3-L1 adipocytes by 
inhibiting PPARγ activity. Meanwhile, Berberine altered lipid metabolic genes in 
adipose tissue, including FAS, AP2, UCP2, and SREBP1c.  
In many experiments and clinic trials, BBR showed antioxidant and anti-
inflammatory effect in the treatment of T2DM and obesity. Mostly, BBR decreases 
oxidative stress, through reducing oxidative stress markers malondialdehyde (MDA), 
increasing antioxidant glutathione (GSH), and promoting activities of antioxidant 
enzymes glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) (41). 
Additionally, AMPK is a key factor in the antioxidant effect of BBR, via down-
regulating NADPH oxidase (42). BBR reduced inflammation response in tissues of liver, 
adipose tissue, kidney and pancreas in diabetes mellitus animals. In cultured HepG2 
cells, liver cells, macrophages, and pancreatic 𝛽-cells, BBR decreased production of pro-
inflammatory cytokines such as TNF-𝛼, IL-6, IL-1𝛽 as well (43,44). It was also reported 
BBR decrease the serum level of IL-6 in T2DM patients. It was considered MAPK 
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signaling pathway play a crucial role in BBR anti-inflammatory activity. MAPK 
phosphorylation was inhibited by BBR in cells treated with inflammatory stimuli like 
lipopolysaccharide (LPS), FFA and TNF- 𝛼. BBR inhibited the nuclear translocation of 
nuclear factor-𝜅B (NF-𝜅B), by reducing I𝜅B kinase-𝛽 (IKK-𝛽) in 3T3-L1 adipocytes (45) 
and liver and adipose tissues in obesity mice, leading to decreased expression of various 
pro-inflammatory cytokines such as TNF-𝛼, IL-6, iNOS and COX2. 
In addition, berberine has been shown benefits in the cardiovascular system, 
antitumor, immune-regulatory, antimalarial, anti-HIV, antidepressant, and against 
polycystic ovary and Alzheimer’s disease, with significant anti-inflammatory activities. 
BBR would inhibit cell proliferation and induce apoptosis in cancer cells, the 
associated mechanisms include impairing cell cycle, inhibiting the telomere elongation, 
increasing p53 protein activity, decreasing prostate cancer cells proliferation via AMPK 
activation, inducing autophagy, and inhibiting folate cycle (46). 
1.2.3 Berberine in the treatment of nonalcoholic fatty liver disease 
A lot of evidences showed the crucial target of berberine in therapy of most of the 
metabolic syndromes focuses on AMPK pathway. As we all know, AMPK is an 
important upstream of most lipid metabolism pathway. Thus, for recent ten years, 
someone thought maybe berberine had some kind of benefits in ameliorating NAFLD as 
well as other metabolic syndromes. 
Additionally, liver was considered to be the main target organ of BBR in vivo. BBR 
metabolites are widely distributed in many tissues, such as liver, kidney, spleen, heart, 
20 
and brain. In animal studies, neither original BBR nor its metabolites could be 
metabolized by human or rat intestinal bacteria flora, but by liver homogenate(33). Thus, 
liver is the primary disposition and metabolic organ for BBR, and BBR has a longer 
half-life in liver than other tissues. After oral administration, the original protoberberine 
was characterized by CYP450 isoenzymes via oxidative demethylation and then 
conjugated by glucuronic acid (47). 
A lot of animal and cell experiments proved the hypothesis. Intracerebroventricular 
injection of 5mg·kg
-1
·day
-1
 BBR in db/db mice, has been shown to promoted fatty acid
oxidation in muscle and liver, leading to alleviate fatty liver. BBR increased fatty acid 
oxidation via activating AMPK expression and inactivating ACC in human HepG2 cells 
(35,48). Similarly, BBR regulates fatty acid metabolism genes in rat primary hepatocytes, 
including SREBP, acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS), and 
stearoyl CoA desaturase 1 (SCD1)(49). Additionally, BBR significantly inhibited IL-6 
and TNF𝛼 in HepG2 cells, and reduced ROS in rat livers(5). BBR lowers cholesterol-
lowering distinct from statins, through up-regulating the low-density-lipoprotein receptor 
(LDLR) independent of SREBPs (4). BBR reduces hepatic fat content in the rats of 
nonalcoholic fatty liver disease, via decreasing methylation of the MTTP promoter (50). 
Berberine improved histological features of NAFLD in high-fat diet fed rats, via up-
regulating IRS-2 mRNA and protein levels in liver (51). BBR may also further prevent 
the development of NASH in liver fibrosis experimental models. BBR supplement may 
restore liver function, because clinical statistic data demonstrated the serum levels of 
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alkaline phosphatase (ALP) and aminotransaminases in type II diabetes patients were 
reduced by BBR (52). 
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2. EXPERIMENTAL AIMS
Conclusively, BBR exhibited the function of anti-hyperglycemic and anti-
hyperlipidemic in metabolic diseases, as well as strong antioxidant and anti-
inflammatory effect. It could improve insulin sensitivity and have beneficial effect of 
anti-hyperlipidemea and cholesterol disorder in NAFLD. However, after ten years of 
study on NAFLD, the molecular mechanism is still unclear. Besides, considering liver is 
the major site of BBR combination and metabolism, in this project, we focus on 
determining which cell types in liver may take the major response to Berberine in the 
NAFLD model. 
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3. MATERIALS AND METHODS
3.1 Diet induced fatty liver mice model 
C57BL/6J WT mice from the Jackson Laboratory were bred on a 12/12-h light-dark 
cycle. Male littermates of 5–6 weeks weighing 20 – 25 g were fed a high-fat diet (HFD, 
60% fat calories, 20% protein calories, and 20% carbohydrate calories) for 12 weeks, 
and in the last 4 weeks they were fed with PBS as a control group or berberine 
(C20H18ClNO4, Sigma-Aldrich, St Louis, MO, USA) (100 mg·kg
-1
·day
-1
, dissolved in
PBS) via oral gavages. Food intake and Body weight were measured every week. In the 
final week, all mice were euthanized, and the epididymal fat pads and the livers were 
weighted and removed, some pieces were stored in -80°C for QPCR and western blot 
analysis, and others were fixed in 10% NBF for Oil-Red-O and H&E staining. 
It has been proved in the previous experiments performed in our laboratory, that the 
HFD-fed mice could serve as an appropriate NAFLD mouse model(53), compared with 
mice fed with low-fat diet (LFD, 10% fat calories, 20% protein calories, and 70% 
carbohydrate calories). In order to simplify the animal experiment groups, we only set 
the HFD-induced NAFLD mice groups in this project, our object focus on the 
therapeutic effects of berberine on fatty liver. Additionally, in order to analyze accurate 
alternation in molecular metabolism, we used several tissue samples of LFD-fed mice. 
All experimental procedures and the animal protocol were approved by Institutional 
Animal Care and Use Committee of Texas A&M University. 
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3.2 Insulin and glucose tolerance tests 
At 12 weeks of HFD, a glucose tolerance test was performed, the mice were fasted 
for 4 hours and then injected with 2 g/kg body weight D-glucose, 5 µl blood samples 
were collected from the tail veins, at 0, 30, 60, 90, and 120 min after the injection. For 
insulin tolerance test, the mice were injected with 1 U/kg BW insulin, and similarly 
blood samples were collected at 0, 15, 30, 45, and 60 min after the bolus insulin 
injection. The plasma glucose levels were all measured via the enzymatic assay kit 
(Sigma, St. Louis, MO). 
3.3 Flow cytometry analysis 
Macrophage isolated from adipose tissue of C57BL/6J mice will be analyzed by 
flow cytometry. 4 fluorescence-colored antibodies, CD11b, F4/80, CD11c and CD206, 
were used to identify mature macrophage (CD11b+ F4/80+), and ratio of M1 
(CD11c+CD206-) and M2 (CD206+ CD11c -). 
3.4 Cell culture 
Rat hepatoma cell line H4IIE cells were cultured in high glucose Dulbecco's 
modified eagle medium (DMEM) with 10% fetal bovine serum, 100 µg/ml streptomycin, 
and 100 units/ml penicillin, at 37 °C in a humidified atmosphere of 95% air and 5% CO2. 
Primary hepatocytes were isolated from WT C57BL/6J mice. After anesthetizing 
the mouse by xylazine (AnaSed, USA, mixture of 100ul ketaset and 10ul xylazine in 1ml 
PBS, 10ul/g body weight of mouse), perfuse the liver with perfusion I (PI, 142mM 
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sodium chloride, 6.7mM potassium chloride, 10mM Hepes, 2.5mM EGTA, pH 7.4) 
from the hepatic portal vein for 5- 10 min, until the liver turns white. Then switch to 
perfusion II with collagenase, it takes 5- 8 min and the liver tissue becomes soft and 
disintegrated. Collagenase need to be active by incubating in 37 °C for 30 min, 50mg 
collagenase (Sigma, St Louis, USA) and 1g fatty acid free albumin (BSA, Sigma, St 
Louis, USA) are dissolved in 100 ml of pre- perfusion II (PII, 66.7mM sodium chloride, 
6.7mM potassium chloride, 100mM Hepes, 4.8mM calcium chloride dihydrate, pH 7.6). 
Gently dissociate cells by shaking the perfused liver, and then suspend the cells in cold 
Medium 199 (9.2g /L Gibco Medium 199 powder, 23mM Hepes, 26mM sodium 
bicarbonate, 11mM D- glucose, 100nM dexamethasone, 100nM insulin, 10% fetal 
bovine serum, 100 µg/ml streptomycin, and 100 units/ml penicillin, pH 7.4). Spin down 
cells 5 min at 4 °C and wash one time, and re-suspend cells in cold Medium 199 again. 
Carefully layer 5ml cells onto 5 ml percoll cushion [1:1 mixture of Medium 199 and 
percoll stock, which containing 45ml percoll (sigma), 5ml 10×PBS, and 0.5ml 1M 
Hepes, pH 7.4], and spin down cells 5 min at 4 °C. Wash the hepatocytes one time, and 
then plate them in plates, which already were coated by coating buffer [0.1ml acetic acid, 
1ml rat tail collagen type I(Corning, Tewksbury, USA), diluted in 100ml dd water]. 
To induce lipid deposition, the hepatocytes were pre-treated 2h with 25mM 
palmitate, and then they were treated by PBS versus berberine (dissolved in DMSO and 
diluted in PBS). 
We isolated bone marrow-derived macrophages (BMDM) from the same back 
ground mice for inflammatory response study. Bone marrow will be isolated from the 
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tibias and femurs of chow diet-fed C57BL/6J male wild-type mice around 12 weeks old. 
After cultured in Iscove's modified Dulbecco's medium (IMDM) with supplement of 10% 
fetal bovine serum and 15% L929 for 7 days, BMDM was change to be incubated in 
normal high glucose DMEM, and treated with LPS  (100 ng/ml, 30 min for cell signaling) 
and BBR. 
3.5 Western blot analysis 
Cells or tissues were lysed in the lysis buffer (20mM Hepes, 100mM sodium 
fluoride, 10mM sodium pyrophosphate, 1% NP-40, 0.1% SDS, 2mM EDTA, 2mM Na 
Vanadate, pH 7.4), and the protein concentration was determined by BCA assay 
(Thermo scientific, USA). Then the protein samples were separated via 8% sodium 
dodecyl sulfate polyacrylamide gels (SDS-PAGE) and transferred to polyvinylidene 
difluoride (PVDF) membranes. The membranes were blocked in 5% milk in TBST for 
4hr at room temperature. Then the membranes were incubated in 1:1000 primary 
antibodies (including P-AMPK/AMPK, P-ACC/ACC, Pp46/p46, and Pp65/p65, 
GAPDH was used as total control) diluted by 5% BSA in TBST at 4 °C overnight. After 
3×5 min washes with TBST, the membranes were incubated for 2hr of secondary 
antibody, and detected with chemi-luminescent reagent. 
3.6 RNA analysis 
Total RNA of cells and frozen tissues were isolated by STAT-60 and reverse 
transcribed into cDNA by the GoScriptTM Reverse Transcription System (Promega), 
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and the relative mRNA expression levels were quantified by quantitative real-time 
polymerase chain reaction (RT-PCR), using SYBR Green (LightCycler® 480 system; 
Roche). The mRNA expression level was normalized by 18S. The sequences of the 
primers include: ACC1, FAS, SREPB1c, CPT1a, arginase 1, adiponectin, and resistin, 
TNFa, IL-1b, IL-6. The results were analyzed by the 2
-ΔCT
 calculation.
3.7 Oil-Red-O staining 
In order to determine the lipid accumulation, the primary hepatocytes and frozen 
livers were stained with Oil-Red-O. After the treatment, the cells were fixed in 75% 
formaldehyde in PBS for 15min, and then stained with Oil-Red-O solution [0.5% stock : 
dd water is 6:4, 0.5% stock (5 mg/ml powder in isoproponal)] for 1h, then washed with 
ddH2O for 3×5 min and take pictures. 
3.8 Statistical analysis 
Data are presented as mean±SE. Two-group differences were detected by Two-
tailed independent Student's t-tests, and P<0.05 were considered significantly. 
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4. RESULTS
4.1 Effect of berberine on the characteristics of the HFD mice 
We induced nonalcoholic fatty liver of C57BL/6J mice with close body weight by 8 
weeks high fat diet feeding. The body weight of the male mice increased from 22 g 
average to around 35g, and the calorie intake remains stable. Then the mice were divided 
into two groups with 4 weeks oral gavage BBR or phosphate-buffered saline (PBS). 
Compared with PBS group, berberine did not affect the body weight of HFD-fed mice 
significantly (Figure 4.1A, HFD-PBS vs. HFD-BBR), as well as the food intake (Figure 
4.1B, HFD-PBS vs. HFD-BBR). The data suggested BBR would not affect the mice 
appetite, even though it tastes bitter. 
4.2 Berberine decreases insulin resistance and glucose intolerance in HFD mice 
Systemic insulin sensitivity was evaluated by glucose tolerance test (GTT) and 
insulin tolerance test (ITT). The GTT test data shows berberine treatment decrease blood 
glucose of HFD mice (Fig 4.2A). The response of plasma levels of glucose to glucose 
peritoneal injection in the BBR – treated mice was more sensitive than the control group. 
The blood glucose of the BBR group increased modest, and the plasma glucose level 
decrease faster than the PBS group. In the ITT test, the blood glucose levels in both of 
the two group exhibited similar decrease after insulin injection, however, the general 
values of different time point were lower in BBR treatment mice (Fig 4.2B). 
29 
Figure 4.1 Neither body weight nor food intake were affected by berberine.  
Fed 5 ~ 6 weeks male C57BL/6J mice with high-fat diet (HFD) for 12 weeks, and 
gavage with phosphate-buffered saline (PBS) as control group or berberine (100 mg·kg-
1·day-1, dissolved in PBS) for 4 weeks. (A) Body weight was measured every week 
during the HFD period. (B) Food intake was measured weekly and the result stands for 
food consumption per mouse/ per day.  
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Figure 4.2 BBR reduced fasting blood glucose and improved insulin sensitivity. 
After 4 weeks of BBR treatment, (A) Effects of BBR treatment on GTT. The mice were 
injected with glucose (2 g/kg body weight) after 4 hr fasting. Data are presented as mean 
± SE (n = 6). (B) Insulin tolerance tests. The mice received an injection of insulin (1 
U/kg body weight). Data are presented as mean ± SE (n = 6 ). *, P<0.05, BBR group 
compared with PBS group at the same time point. 
A
B
0
100
200
300
400
500
600
700
0' 30' 60' 90' 120'
P
la
sm
a 
gl
u
co
se
 le
ve
ls
 (
m
g/
d
l)
 
GTT 
PBS
Ber
* 
* 
* 
0
50
100
150
200
250
300
350
0' 15' 30' 45' 60'
P
la
sm
a 
gl
u
co
se
 le
ve
ls
 (
m
g/
d
l)
 
ITT 
PBS
Ber
*
31 
Therefore, it seems like berberine treatment decreases fasting glucose level, and 
ameliorates glucose intolerance and insulin resistance without changing body weight and 
food intake in HFD mice. 
4.3 Berberine decreases HFD-induced lipid accumulation in hepatic steatosis 
At the last week of HFD, we dissected the mice, and the livers were removed and 
weighed. Compared with PBS-treated mice, liver weights of BBR-treated mice exhibited 
a slight decrease (Fig 4.3A). The pictures show the fat content is less in the liver sections 
with Oil-Red-O staining of BBR mice, than the PBS group (Fig 4.3B). Given this, it 
denominates treatment of BBR ameliorated lipid deposition and steatosis in obese mice. 
4.4 Berberine altered lipid metabolism and related protein and genes expression 
       We isolated total protein of liver and examined AMPK in the liver (Fig. 4.4A).  
AMPK phosphorylation was reduced in the HFD-fed mice slightly, compared with  LED-
fed mice. However, we did not observe that BBR treatment reverse decreased AMPK 
phosphorylation induced by HFD significantly. We also detected the substrate enzyme 
of AMPK, ACC, which is the key enzyme in lipogenisis. The phosphorylation of ACC 
in the HFD-fed mice decreased as well as AMPK phosphorylation (Fig 4.4A), thus the 
active ACC will convert Acetyl-CoA to Malonyl-CoA, and increase production of fattty 
acid in liver. Consistently, BBR did not alter the phosphorylation of ACC of HFD mice. 
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Figure 4.3 Berberine treatment ameliorates fat content in liver.  
The HFD-induced NAFLD animal model was built as described, and all mice were 
euthanized and the livers were harvested. (A) BBR treatment altered the liver weight. (B) 
Liver sections with Oil-Red-O staining. The Oil-Red-O marked the lipid drops as the red 
dot shown in the picture. 
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Figure 4.4 Berberine reduced the expression of lipogenic genes in liver.  
The HFD-induced NAFLD animal model was built as described in Figure 4.1, and 
expression of protein and mRNA levels in liver was examined. (A) Expression and 
phosphorylation of AMPK (Thr172) and ACC, loading control is GAPDH. Liver protein 
expression was measured by Western blot analyses. Ratios of phosphorylated AMPK to 
total AMPK (P-AMPK/AMPK) and phosphorylated ACC to total ACC (P-ACC/ACC) 
were quantified using densitometry and normalized by GAPDH (AU, arbitrary unit). (B) 
mRNA levels of lipid metabolic related genes in liver were analyzed by QPCR. Data are 
presented as mean ± SE (n = 3). *, P<0.05, HFD-BBR group compared with HFD-PBS 
group; Ϯ, P<0.05, HFD-PBS group compared with LFD-PBS group. 
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Meanwhile, we measured the mRNA expression of lipogenesis related genes. 
ACC1, FAS, and the transcription factor SREBP1c play a key role in lipogenesis process. 
Obviously, BBR treatment decreased the levels of ACC1, FAS, and SREBP1c in high-
fat diet mice (Fig 4.4B). These data suggest the lipogenesis pathway may be blocked by 
BBR, therefore, fatty acid synthesis should be inhibited. But the weird thing is the 
expression level of CPT1a in the liver did not decrease. Combined with results of Oil-
Red-O staining liver, maybe the suppressed effect of BBR in lipogenesis is stronger, and 
the lipid accumulation amount is less than β oxidation of fatty acids, although the 
oxidation in BBR group is slow at the same time. 
4.5 Berberine inhibits HFD-induced inflammation in liver 
Inflammation was considered to promote steaosis to NASH, and pro-inflammatory 
cytokines such as TNFa and IL-6 are the most important factors. Firstly, in the 
experiment we examined the phosphorylation of JNK of liver tissue. We can see the 
phosphorylation of JNK1 (p46) in livers of HFD-fed mice increased statistically 
significantly, compared with that of LFD-fed mice (Figure 4.5A). Upon BBR treatment, 
the phosphorylation of liver JNK1 declined. Secondly, we examined the mRNA 
expression levels of proinflammatory cytokines including TNFα, IL-1β and IL-6. All of 
them were greatly activated by the high-fat diet, whereas both of TNFα and IL-1β are 
reduced under the treatment of BBR (Figure 4.5B). But the induced IL-6 in liver was not 
affected by BBR. Thus, these results denominate BBR significantly inhibitor 
inflammatory signaling in liver of HFD mice. 
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Figure 4.5 Berberine reduced HFD-induced inflammatory responses in liver.  
The HFD-induced NAFLD animal model was built as described in Figure 4.1, and 
expression of protein and mRNA levels in liver was examined. (A) Expression and 
phosphorylation of JNK, loading control is GAPDH. Liver protein expression was 
measured by Western blot analyses. Ratio of phosphorylated JNK1 to total JNK1 
(Pp46/p46) was quantified using densitometry and normalized to GAPDH. (B) mRNA 
levels of pro-inflammatory cytokines in liver were analyzed by QPCR. Data are 
presented as mean ± SE (n = 2). *, P<0.05, HFD-BBR group compared with HFD-PBS 
group, **, P<0.01, HFD-BBR group compared with HFD-PBS group; Ϯ, P<0.05, HFD-
PBS group compared with LFD-PBS group, ϮϮ, P<0.01, HFD-PBS group compared with 
LFD-PBS group. 
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4.6 Berberine activated AMPK phosphorylation and inhibited HFD-induced 
inflammation in adipose tissue 
In obese, pro-inflammatory cytokines secreted by adipose tissue, such as JNK1 - 
dependent IL-6 secretion, were thought to aggravate inflammation in NASH. Part of 
epididymis adipose tissues were used for analysis of protein and mRNA levels. It was 
difficult to get enough adipose tissue from LFD-fed mice to perform these assays, so we 
only used HFD-fed mice in order to make the result consistent. It is shown (Figure 4.6A) 
that BBR treatment increase AMPK phosphorylation in HFD-fed mice. Then we 
examined mRNA levels of arginase 1, adiponectin, and resistin, which are related to 
functions of adipose tissue and the inflammatory response. It seems like arginase 1 and 
adiponectin increase, and resistin decrease in the BBR group mice (Figure 4.6B), but the 
results are not statistically significant. 
Next, we examined the phosphorylation of JNK 1 (p46) in adipose tissue, and BBR 
treatment decrease the phosphorylation of JNK1 obviously (Figure 4.6A). Meanwhile, 
we measured the mRNA expression of TNFα, IL-1β and IL-6. All of them were reduced 
in the BBR treatment group (Figure 4.6C). 
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Figure 4.6 Berberine activated AMPK phosphorylation and inhibited HFD-induced adipose tissue 
inflammation.  
The HFD-induced NAFLD animal model was built as described in Figure 4.1, and expression of protein and mRNA 
levels in liver was examined. (A) Expression and phosphorylation of AMPK (Thr172) and JNK, the loading control is 
GAPDH. Protein expression was measured by western blot analyses. Ratios of phosphorylated AMPK to total AMPK 
(P-AMPK/AMPK) and phosphorylated JNK1 to total JNK1 (Pp46/p46) were quantified using densitometry and 
normalized to GAPDH. (B) mRNA levels of adipocytokines were analyzed by QPCR. (C) mRNA levels of pro-
inflammatory cytokines in adipose tissue. (D) FACS analysis of adipose tissue stromal vascular cells. Data are 
presented as mean ± SE (n = 3). *, P<0.05, BBR group compared with PBS group; **, P<0.01, BBR group compared 
with PBS group. 
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Alternation of the ratio of type 1 macrophages and type 2 macrophages in the 
adipose tissue was also analyzed. Stromal vascular cells (SVC) were isolated from 
epididymis fat pads of PBS and BBR group mice and run the FACS analysis. The 
number of total macrophage increased in BBR treated mice, and this may be related with 
the function of BBR to activate macrophage reported in the research of antitumor. The 
ratio of M1 macrophages, the pro-inflammatory macrophages, was reduced by BBR 
treatment, while the anti-inflammatory activated M2 macrophages had no significant 
difference (Figure 4.6D). 
Totally, treatment of BBR may alter lipid metabolism and inhibit adipose tissue 
inflammation induced by high-fat diet. 
4.7 Berberine dose-dependently suppresses JNK signaling in H4IIE cells 
There are many different types of cells in the liver tissue, the function cell and the 
kuffer cells are considered the major cells involved in NAFLD. In order to determine 
which type of cell play a more important role in fatty liver disease and which type of cell 
will response to the treatment of berberine, we isolated and treated them separately. 
At first, we use a rat hepatoma cell line, H4IIE cells, to identify the appropriate 
dose and time point of BBR treatment in vitro. H4IIE cells were incubated for 6 h and 
24h with increasing concentrations of BBR (1, 5, 10, 25, 50, 100 μM). When in the 
absence of BBR, palmitate increased the phosphorylation of JNK 1 (p46), and at both of 
the two time points, BBR inhibit JNK 1 phosphorylation, and the effective is strength 
under the increasing doses, either incubated with palmitate or not (Figure 4.7A). 
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Figure 4.7 Berberine inhibits JNK phosphorylation dose-dependently and time- dependently in H4IIE cells.  
H4IIE cells were pre-treated 2h with BSA or 25mM palmitate (diluted in BSA) before BBR added. (A) H4IIE cells 
were treated with various concentrations of BBR for 6h or 24h. (B) Incubate H4IIE cells with 25μM BBR and collect 
the protein samples at different time points. Protein levels were determined by Western blot. 
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It was suggested the high dose beyond 50 μM was toxic for the hepatocytes and 
would induce apoptotic program detected by flow cytometry (54), thus we chose 25μM 
concentration to decide the time point that BBR have the best anti-inflammation effect. 
H4IIE cells were treated with BBR for 10 min to 24 hr, and the effective was as more 
powerful as longer time. Stared from 4h, the phosphorylation of JNK 1 was mostly 
inhibited under palmitate treated environment, and the effect remained even until 24 h 
(Figure 4.7B). Therefore, we selected 25 μM and 4h as a suitable BBR treatment 
condition to treat the cells in ongoing experiments. It should be specifically mentioned 
that the phosphorylation of AMPK did not affected by BBR in H4IIE cells. 
4.8 Berberine reduced fat deposition and inflammatory responses in primary 
hepatocytes 
As described in the animal experiments above, it seems like the liver is the target of 
the anti-inflammation effective of berberine in NAFLD obesity mice. In order to try to 
learn the true response of the hepatocytes to berberine, we isolated the primary 
hepatocytes of C57BL/6J male mice. After Oil-Red-O staining, we could observe 
palmitate would induce fat deposition in the hepatocytes, and BBR reversed the effect 
partly (Figure 4.8A). 
The primary hepatocytes were treated by 25μM BBR for 1h or 4h, in the presence 
or absence of palmitate. It was obvious phosphorylation of JNK 1 was inhibited at 4h, 
and the phosphorylation of AMPK of both 1h and 4h increased significantly (Figure 
4.8B). 
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For 4h of BBR treatment, we also identified the effect of various doses of BBR on 
primary mouse hepatocytes. 5μM BBR is enough to suppress the activity of 
phosphorylated JNK in absence of palmitate, but the most appropriate concentration still 
is 25μM upon palmitate incubation (Figure 4.8C). All of the doses significantly activate 
the phosphorylation of AMPK in the primary hepatocytes. 
Figure 4.8 Berberine reduced fat deposition and inflammatory responses.  
Induce fat deposition in primary hepatocytes with 6h treatment of palmitate. (A) Fat 
deposition in hepatocytes. The red dots were lipid drops stained by Oil-Red-O. (B) 
Western blot analyses of phosphorylation of AMPK (Thr172) and JNK, GAPDH as 
control. The primary hepatocytes were treated with 25μM BBR for different hours. (C) 
Treat the primary hepatocytes with different concentrations of BBR for 4h and analyze 
protein expression. 
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Figure 4.8 Continued 
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Generally, the anti-inflammation effective of berberine in primary mouse 
hepatocytes is similar with that in H4IIE cells, the difference is BBR induced the 
phosphorylation of AMPK. 
4.9 BBR treatment did not inhibit macrophage pro-inflammatory activation 
It is difficult to separate Kupffer cells from liver tissue, so we bone marrow derived 
macrophages (BMDM) at first to test the macrophages inflammatory response to BBR. 
Short-term treatment of LPS is enough to induce strong inflammatory response in 
macrophages, the phosphorylation of both JNK 1 (p46) and NF-κB p65 (Ser536) was 
significantly activated (Figure 4.9). However, BBR did not change the activation 
response at all. This result suggests maybe the macrophages are not the major anti-
inflammation target of BBR. Metformin treatment was set as a positive control. 
4.10 Effect of BBR treatment in insulin signaling pathway 
We treated the primary hepatocytes by 25μM BBR for 4h, in the presence or 
absence of 2h pre-treatment of palmitate. In baseline, the phosphorylation of Akt was 
induced by 30 min insulin treatment. However, BBR inhibited the activity of p-Akt, 
independent of palmitate incubation. In the other hand, the alternation of AMPK and 
JNK 1 (p46) phosphorylation by BBR was not affected by insulin, remains the same 
increased or decreased level (Figure 4.10). Similarly as described in the liver tissue 
previously, the phosphorylation of ACC in the primary mouse hepatocytes was enhanced 
by BBR, in the absence of palmitate. Generally speaking, the activity of ACC was 
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slightly inhibited by the incubation of palmitate, and it is reasonable in the balance of 
chemical responses. However, after 30 min treatment of insulin, the inhibit effect of 
BBR on activity of ACC was abolished, under the incubation of palmitate. 
Figure 4.9 BBR treatment has no effect on macrophage proinflammatory activation. 
Bone marrow-derived macrophages (BMDM) were treated with PBS, BBR(25 µM, 4hr), 
or metformin (500 µM, 24hr), and LPS (100 ng/ml, 30 min) was used to induce 
inflammatory response. Macrophage inflammatory signaling was examined by Western 
blot analysis. 
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Figure 4.10 Berberine change the insulin signaling and related protein expression. 
Treat the primary mouse hepatocytes as described in Figure 4.8, and at the last 30 min, 
add insulin (100nM). Western blot analyses of phosphorylation of Akt, ACC, AMPK 
(Thr172) and JNK, GAPDH as control. 
46 
5. CONCLUSION
5.1 Conlusion 
In the results of HFD animal experiments, berberine improved insulin resistance 
and glucose intolerance in HFD mice, without changing body weight and food intake. 
One month treatment of berberine ameliorates fat deposition in liver, through reducing 
lipogenesis related proteins and genes expression. As well as the anti-inflammatory 
effect showed in other metabolic syndromes, berberine decreased inflammatory 
signaling in liver and adipose tissue in HFD mice, such as JNK pathway and cytokines 
including TNFa and IL-6. In cell experiments, we detected responses induced by BBR in 
macrophages and hepatocytes, which are the major cells associated with fatty liver. 
However, the cultured macrophages didn't show significant difference in inflammatory 
responses. Adversely, JNK1 phosphorylation in both of the cell line and primary 
hepatocytes was inhibited by BBR. Thus, we can hypothesize hepatocytes is the main 
cell included in the beneficial effect in NAFLD of BBR. Moreover, the phosphorylation 
of AMPK in primary hepatocytes increase under the treatment of BBR, but the H4IIE 
cells didn't, maybe because of the different energy metabolism in the cancer cell line. 
Additionally, BBR inhibited the insulin signaling response in primary mouse 
hepatocytes. Specifically, berberine reduced the activity of ACC, but the effect was 
interrupted by increased insulin level, in the high fat model supplemented by palmitate, 
without affecting the alternation of AMPK. 
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5.2 Discussion 
In our cell experiment, BBR blocked the phosphorylation of Akt induced by insulin, 
and it is consistent with responses in other cell types, such as MDA-MB-231 cells (55) 
and intestinal cell (56). But it already mentioned that berberine would decrease glucose 
levels in humans and animals (37,39,57), and increase glucose uptake in related cells, 
such as in 3T3-L1 adipocyes (58). Someone demonstrated maybe the anti-hyperglycemic 
effect was not related to insulin pathway. According to the experiments performed by 
Zhang et al. (57) in KKAy mice, a model of severe obesity, hyperinsulinemia and 
glucose intolerance by transferring yellow obesity (Ay) gene into the KK strain, our 
results are consistent with their results of insulin signaling molecules showed in the 
DNA microarrays. They also considered insulin signaling pathway was not important in 
the effect of berberine on regulating glucose metabolism. It is also reported BBR did not 
change p-Akt in the liver after 30 minutes insulin challenge in HFD Sprague-Dawley 
rats (39). Thus, we may suggest BBR would inhibit hyperinsulinemia-induced 
lipogenesis and associated genes levels through Akt pathway, and it does not mean 
exacerbated insulin resistant. Together with the increased insulin sensitivity we showed 
in BBR-treated HFD mice, BBR may ameliorate hyperglycemia via a mechanism 
distinct from insulin, meanwhile BBR reduce fat storage in hepatic steaosis through 
inhibition of insulin signaling pathway. 
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Figure 5.1 Summary of effect of berberine in NAFLD in our project.  
BBR may improve NAFLD through inhibiting lipogenesis and inflammatory responses 
in liver and adipose tissue. 
In HFD mice, we found BBR activated AMPK and reduced levels of inflammatory 
cytokines in adipose tissue, specifically inhibited phosphorylation of JNK1 and IL-6 
gene expression, which was suggested to play an key role in inflammatory process in 
NASH development (17). In liver, JNK, TNFa and IL-1β were decreased by BBR as 
well, but it seems like IL-6 is not be affected. We may hypothesize diet-induced 
inflammation in adipose tissue is also important in beneficial effect of berberine in 
improvement of hepatic steatosis, but it needs further experiments. In liver and other 
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possible related organs, it seems like BBR has good pharmacological effect in 
inflammation in NAFLD, which is the main reason to develop NASH from steatosis. 
Maybe BBR will have a better performance in anti-NASH, we can identify it in 
methionine and choline deficient (MCD) diet fed animals or long-termed HFD mice in 
further study, shown as Figure 5.1. 
Even though the blood concentrations of BBR and its metabolites are low, three 
months of oral intake of a much lower dose of BBR than in animal experiments is 
enough to decrease serum triglyceride and fasting and postprandial blood glucose levels 
in T2DM patients. Therefore, according to obviously higher concentration in organs 
including the liver and kidney than in blood, BBR has potential effect to treat NAFLD 
individuals, but it needs more clinic trials data. In our experiments, the effect of BBR in 
liver seems not to be so sensitive in hepatocytes, maybe because the metabolism of BBR 
is different in vitro and vivo. In humans clinic data, the blood concentration of BBR and 
its metabolites after a chronic oral administration of 15 mg·kg
-1
·day
-1
 berberine for three
months, were several folds higher than that after a cute administration of a single dose of 
500 mg·kg
-1
·day
-1
 (59). It suggested long-termed and low dose treatment of BBR may be
more effective than short-termed and high dose. 
Because of the low absorption of BBR and the re-absorption of metabolites from 
jejunum, most of the compound and its metabolic product will stay long time in the 
intestine. In this case, we could think that berberine may affect intestine flora 
metabolism, such as secretion of LPS and pro-inflammatory factors (17). Then the 
inflammatory signaling from the macrophages or epithelial cells, which will affect 
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NASH development, may be altered. Additionally, in research of bacteria-induced 
epithelium damage, berberine can ameliorate inflammatory cytokines secretion from 
intestinal epithelial cells, including TNFα and NFκB (56). 
Collect all the results from laboratory research and clinic data, berberine could be 
considered to use in the treatment of NAFLD, and it surely needs more support. The 
long history utilization of BBR has identified the safety in humans. No sample of serious 
side effects of BBR was reported (3) (such as hepatotoxicity or renal failure), except 
similar gastrointestinal effects as metformin. 
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